Cellectar Biosciences Announces Pricing of $7,000,000 Public Offering

Apr 15, 2016

Cellectar Biosciences Receives Positive NASDAQ Listing Determination

Apr 7, 2016

Cellectar Biosciences Announces Year End 2015 Financial Results

Mar 10, 2016

Cellectar Biosciences to Present at the 28th Annual Roth Capital Conference

Mar 8, 2016

Cellectar Biosciences to Host Conference Call on March 10 to Report Year End 2015 Financials, Corporate Performance and 2016 Objectives

Mar 7, 2016

Cellectar Biosciences Announces 1-for-10 Reverse Stock Split

Mar 4, 2016

Cellectar Biosciences to Present at the 2016 Biotech Showcase

Jan 7, 2016

Cellectar Biosciences Announces Positive Data From Phase 1 Therapeutic Trial of CLR 131 in Multiple Myeloma

Jan 5, 2016

Cellectar Biosciences and Pierre Fabre Laboratories Announce Oncology Research Collaboration

Dec 16, 2015

Cellectar Biosciences to Provide Update on Phase 1 Multiple Myeloma Study

Dec 9, 2015